Q4 2025 Veracyte Inc Earnings Call Transcript
Key Points
- Veracyte Inc (VCYT) reported a 19% year-over-year revenue growth in Q4 2025, reaching $141 million.
- The company's core testing business showed strong performance, with a 21% growth driven by increased volume and average selling price (ASP).
- Veracyte Inc (VCYT) achieved a significant milestone by providing clinically actionable information to nearly 170,000 patients in 2025.
- The company surpassed its adjusted EBITDA margin target, achieving 27.6% for the full year 2025, ahead of its 25% target.
- Veracyte Inc (VCYT) is on track to launch two major products in 2026, including the True MRD test for bladder cancer and Prosigna for breast cancer, which are expected to drive future growth.
- Veracyte Inc (VCYT) faces potential headwinds from prior period collections (PPCs), which are not included in the 2026 guidance and could impact revenue.
- The company anticipates a lower adjusted EBITDA margin in Q1 2026 due to typical seasonality and increased expenses.
- There is uncertainty regarding the reimbursement strategy and pricing for the True MRD test, which could affect its market adoption.
- Veracyte Inc (VCYT) is not including revenue from new product launches in its 2026 guidance, indicating a cautious approach to forecasting.
- The company's non-testing revenue is expected to be lower in 2026 due to the transition to a new contract manufacturer and the decision not to sell IVD products to US customers ahead of the LDT launch.
Good day and thank you for standing by. Welcome to the Verisite 4th quarter 2025 financial results webcast.
At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised.
To withdraw your question, please press 11 again.
Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Sheila Gorman, senior director of investor relations.
Please go ahead.
Good afternoon everyone, and thank you for joining us today for a discussion of our 4th quarter and full year 2025 financial results. With me today are Mark Stay, Farisite's Chief Executive Officer, and Rebecca Chambers, our Chief Financial Officer. Dr. John Light, our Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
